Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Nicola Cresti

Newcastle AuthorsTitleYearFull text
Dr Nicola Cresti
Professor Ruth Plummer
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine2019
Ali Kucukmetin
Dr Nicola Cresti
Dr Rachel O'Donnell
BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature2019
Dr David Jamieson
Dr Jo Lee
Dr Nicola Cresti
Melanie Griffin
Julieann Sludden
et al.
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil2014
Professor Ruth Plummer
Dr Nicola Cresti
Dr Yvette Drew
Dr Peter Stephens
Dr Jared Thornton
et al.
Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma2014
Dr Nicola Cresti
Professor Ruth Plummer
A phase 1 study of oral rucaparib in combination with carboplatin2013
Dr Nicola Cresti
Dr Yvette Drew
Professor Ruth Plummer
A phase I study of oral rucaparib in combination with carboplatin2013
Dr Nicola Cresti
Dr Chris Plummer
Cardiac troponin release following standard dose anthracycline-based adjuvant chemotherapy2013
Dr Nicola Cresti
Professor Ruth Plummer
Pharmacokinetics of eribulin mesilate in combination with capecitabine in patients with advanced/metastatic cancer: Results from a phase IB dose-escalation study2012
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Dr Nicola Cresti
Dr David Jamieson
The pharmacology of trastuzumab and its use in breast cancer2010
12